Type 2 diabetes: principles of pathogenesis and therapy (Q36095054)

12 August 2017

1 reference

title

Type 2 diabetes: principles of pathogenesis and therapy (English)

1 reference

12 August 2017

0 references

0 references

1

Michael Stumvoll

1 reference

12 August 2017

Barry J Goldstein

2

1 reference

12 August 2017

Timon W van Haeften

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

365

1 reference

12 August 2017

1333-1346

1 reference

12 August 2017

9467

1 reference

Global and societal implications of the diabetes epidemic

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Prevalence of impaired glucose tolerance among children and adolescents with marked obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Mitochondrial diabetes: molecular mechanisms and clinical presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Risk of diabetes in offspring of parents with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Prevalence of Diabetes and Glucose Intolerance in 199 Offspring of Thirty-seven Conjugal Diabetic Parents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Heritability of features of the insulin resistance syndrome in a community-based study of healthy families

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Family and genetic studies of indices of insulin sensitivity and insulin secretion in Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Familial resemblance for glucose and insulin metabolism indices derived from an intravenous glucose tolerance test in Blacks and Whites of the HERITAGE Family Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Metabolic and genetic influence on glucose metabolism in type 2 diabetic subjects--experiences from relatives and twin studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

1 reference

7 January 2021

Carbohydrate metabolism in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Failure of adipocyte differentiation causes type II diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Intramyocellular lipids and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Extended longevity in mice lacking the insulin receptor in adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Role of brain insulin receptor in control of body weight and reproduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

IRS proteins and the common path to diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Insulin resistance: a phosphorylation-based uncoupling of insulin signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Cellular mechanisms of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Molecular mechanisms of insulin resistance and the role of the adipocyte

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Adiponectin: A novel adipokine linking adipocytes and vascular function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Prevention of fat-induced insulin resistance by salicylate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Obesity-induced inflammatory changes in adipose tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Disturbances in beta-cell function in impaired fasting glycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Altered homeostatic adaptation of first- and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess beta-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Candidate genes for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Thiazolidinediones: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

PPARgamma, the ultimate thrifty gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Molecular insights into insulin action and secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Growing evidence for diabetes susceptibility genes from genome scan data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from studies of the calpain-10 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Characterization and expression of calpain 10. A novel ubiquitous calpain with nuclear localization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Structure, activation, and biology of calpain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin resistance, and impaired acute insulin secretion among Scandinavian Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Genetic variations in calpain-10 gene are not a major factor in the occurrence of type 2 diabetes in Japanese

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Association of the calpain-10 gene with type 2 diabetes mellitus in a Mexican population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Calpains play a role in insulin secretion and action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The insulin gene VNTR, type 2 diabetes and birth weight.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

1 reference

7 January 2021

Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Progress with thiazolidinediones in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Glitazones and the management of insulin resistance: what they do and how might they be used

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

1 reference

7 January 2021

Antiatherogenic properties of metformin: the experimental evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

The role of sulphonylureas in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Insulin as an anti-inflammatory and antiatherosclerotic hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Therapeutic strategies based on glucagon-like peptide 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2961032-X

7 January 2021

10.1016/S0140-6736(05)61032-X

Identifiers

DOI

1 reference

release_ibcv5ojxxfbdrhqcx5zyfp5q6q

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ibcv5ojxxfbdrhqcx5zyfp5q6q

24 November 2022

mapped directly with Wikidata item

1 reference